IMHO, I assume that funds and institutional investors understand P values and statistical significance better than I. And more importantly have line of sight to many more points on the immuno-oncology scientific horizon.
What else would they base their decisions on than study data? If I do it, surely they do.
Hence, I take confidence in my amateur tape reading over the last few months.
Looking forward to 2021 results anns.
GLTA.
The Importance of P values to clinical trials, page-15
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $216.1K | 4.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 1854997 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 382882 | 4 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |